article thumbnail

The Traditional Pharma Model Isn’t Working – It’s Time to Evolve!

PharmaKinnex

More convenience and safety? Bearing the brunt of these COVID19 restrictions, pharmaceutical reps have had a hard time getting in the door to make sales, and their employers have noticed: Limited In-Person Access To HCPs. Fewer Networking & Industry Trade Show Events. What’s not to love? Higher Travel & Marketing Costs.

Pharma 52
article thumbnail

Paving the way for anti-Abeta active immunotherapy

European Pharmaceutical Review

7 It is currently being evaluated in a Phase Ib/IIa clinical study, demonstrating to date a good safety profile. While favourable safety has been reported up to the Phase II, the relevance of targeting the C-terminal portion of Abeta still needs to be confirmed.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

The Dark Side of the Pharmaceutical Industry: Are Treatments Being Blocked for Profit?

Pharma Marketing Network

This involves paying researchers and scientists to publish articles or conduct studies that support the use of a particular drug, while suppressing or ignoring research that casts doubt on the drug’s safety or efficacy. Pharmaceutical research and development: what do we get for all that money? References: 1.

article thumbnail

Dawn of a new indication: how to study drugs for aging 

Pharmaceutical Technology

Based on preclinical research for their impact on aging, well-known drugs like metformin and rapamycin are already being considered for off-label usage, due to their accepted safety profile and cost-effectiveness.

FDA 145